Sponsor pipeline

Tianjin Medical University Second Hospital clinical trial pipeline

Get alerts when Tianjin Medical University Second Hospital's trials change

26 active trials 19 recruiting 1 Phase 3 3 disease areas 2 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

Show 1 trial with minor changes only
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1/2
2
Phase 2
12
Phase 2/3
1
Not charted: 11 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 26

NCT IDTitleConditionStatusUpdated
Phase 2/3
NCT07756008 Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic… Bladder Urothelial Carcinoma Not Yet Recruiting 2026-08-10
Phase 2
NCT07712029 Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid… Advanced Refractory Solid Tumors Recruiting 2026-07-17
NCT05837806 Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant… Neoadjuvant Immunotherapy Recruiting 2026-07-14
NCT07475403 Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk… Bladder Cancer Recruiting 2026-05-26
NCT07233252 Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer Renal Pelvic Carcinoma Recruiting 2025-11-18
NCT07179783 Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive… Prostate Cancer (Adenocarcinoma) Recruiting 2025-09-18
NCT07172386 Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With… Renal Cell Carcinoma (RCC) Recruiting 2025-09-16
NCT07170293 Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid… Solid Cancers Recruiting 2025-09-12
NCT07126119 Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC Upper Tract Urothelial Carcinoma Recruiting 2025-08-17
NCT07125547 Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral… Ureteral Cancer Recruiting 2025-08-15
NCT06739395 Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard… Solid Tumor Recruiting 2024-12-18
NCT07625527 Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in… Bladder (Urothelial, Transitional Cell) Cancer Not Yet Recruiting 2026-06-04
NCT06584435 A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer High-risk Renal Cell Carcinoma Active, Not Recruiting 2025-12-19
Phase 1/2
NCT06895733 Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With… Solid Tumor, Adult Recruiting 2025-03-26
NCT06663007 RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With… Prostate Cancer Recruiting 2024-10-29
Not applicable
NCT07749924 Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined… Bladder Cancer Recruiting 2026-10-09
NCT07187635 Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of… Bladder Cancer Recruiting 2026-08-14
NCT07321197 Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal… Renal Cell Carcinoma (Kidney Cancer) Recruiting 2026-06-25
NCT07321210 Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk… Upper Tract Urothelial Carcinoma Recruiting 2026-06-25
NCT07180212 Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk… Bladder Cancer Active, Not Recruiting 2026-09-28
NCT07172373 Safety and Effectiveness of Antegrade Flexible Ureteroscopy-Assisted Percutaneous… Urolithiasis Not Yet Recruiting 2025-09-15
Not specified
NCT07657325 Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk… Renal Cell Carcinoma (RCC) Recruiting 2026-06-18
NCT07130578 The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second… Bladder Cancer Recruiting 2026-03-03
NCT07441499 Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial… Urothelial Carcinoma (UC) Recruiting 2026-03-02
NCT07697417 Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic… Renal Cell Carcinoma Active, Not Recruiting 2026-07-13
See all 26 active Tianjin Medical University Second Hospital trials with filters →

Disease areas by active trials

Bladder Cancer (10) · Kidney Cancer (5) · Prostate Cancer (2)

Get alerts when Tianjin Medical University Second Hospital's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free